Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 12/20 | 0.34 |
| ▸ | HTR2C | P28335 | 4/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482775 | 0.92 | HTR2C (0.34) | PDE2AHTR2CSLC6A4HTR2A | |
| SCHEMBL4493516 | 0.90 | PDE2A (0.37) | PDE2A | |
| SCHEMBL4486630 | 0.81 | PDE2A (0.37) | PDE2A | |
| SCHEMBL3223559 | 0.78 | PDE2A (0.38) | PDE2A | |
| SCHEMBL4488290 | 0.77 | PDE2A (0.35) | PDE2A | |
| SCHEMBL4494835 | 0.77 | PDE2A (0.35) | PDE2A | |
| SCHEMBL4494001 | 0.77 | PDE2A (0.35) | PDE2A | |
| SCHEMBL4501144 | 0.76 | PDE2A (0.41) | PDE2A | |
| SCHEMBL4480515 | 0.75 | PDE2A (0.39) | PDE2A | |
| SCHEMBL4486210 | 0.75 | PDE2A (0.35) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507739-B2 | 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1680425-B1 | 6- [(SUBSTITUTED)PHENYL] TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH CORP (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | WYETH HOLDINGS CORPORATION (US) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090508-A1 | 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents | ABCC1, ABCB1, TUBB6 | PDE2A 3428/4885HTR2C 4541/4885SLC6A4 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.